Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome

Kidney International

Volumn 84, Issue 5, 2013, Pages 1025-1033

  Ravani, Pietro ^a   Ponticelli, Alessandro ^b   Siciliano, Chiara ^b   Fornoni, Alessia ^c   Magnasco, Alberto ^b   Sica, Felice ^d   Bodria, Monica ^b   Caridi, Gianluca ^b   Wei, Changli ^c   Belingheri, Mirco ^e   Ghio, Luciana ^e   Merscher Gomez, Sandra ^c   Edefonti, Alberto ^e   Pasini, Andrea ^f   Montini, Giovanni ^f   Murtas, Corrado ^b   Wang, Xiangyu ^a   Muruve, Daniel ^a   Vaglio, Augusto ^g   Martorana, Davide ^g   Pani, Antonello ^h   Scolari, Francesco ⁱ   Reiser, Jochen ^j   Ghiggeri, Gian M ^b   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Hospital of Foggia   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY HOSPITAL OF PARMA   (Italy)

^h BROTZU HOSPITAL   (Italy)

ⁱ Ospedale di Montichiari   (Italy)

^j RUSH MEDICAL COLLEGE   (United States)

more..

Author keywords

clinical trial; nephrotic syndrome; pediatrics; proteinuria

Indexed keywords

CALCINEURIN INHIBITOR; CD20 ANTIGEN; CYCLOSPORIN; FC RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ARTHRITIS; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LUNG INJURY; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RELAPSE; REMISSION; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; NEPHROTIC SYNDROME; PHOSPHORYLATION; PODOCYTES; POLYMORPHISM, GENETIC; PREDNISONE; PROSPECTIVE STUDIES; RECEPTORS, IGG; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; SPHINGOMYELIN PHOSPHODIESTERASE; SRC-FAMILY KINASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888383730     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.211     Document Type: Article

References (31)

1. Braden GL, Mulhern JG, O'Shea MH et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35: 878-883.
2. Trompeter RS, Lloyd BW, Hicks J et al. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 1985; 1: 368-370.
3. Ponticelli C, Rizzoni G, Edefonti A et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377-1384.
4. Ghiggeri GM, Catarsi P, Scolari F et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004; 26: 1411-1418.
5. Kyrieleis HA, Lowik MM, Pronk I et al. Long-term outcome of biopsyproven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009; 4: 1593-1600.
6. Ghiggeri GM, Altieri P, Oleggini R et al. Cyclosporine enhances the synthesis of selected extracellular matrix proteins by renal cells "in culture". Different cell responses and phenotype characterization. Transplantation 1994; 57: 1382-1388.
7. Stashenko P, Nadler LM, Hardy R et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1685.
8. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-182.
9. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548-551.
10. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613-626.
11. Nozu K, Iijima K, Fujisawa M et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1660-1663.
12. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354: 1961-1963.
13. Magnasco A, Ravani P, Edefonti A et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012; 23: 1117-1124.
14. Guigonis V, Dallocchio A, Baudouin V et al. Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279.
15. Gulati A, Sinha A, Jordan SC et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5: 2207-2212.
16. Kemper MJ, Gellermann J, Habbig S et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-1915.
17. Ravani P, Magnasco A, Edefonti A et al. Short-term effects of rituximab in children with steroid-and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1308-1315.
18. Fornoni A, Sageshima J, Wei C et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.
19. Chaumais MC, Garnier A, Chalard F et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24: 1753-1755.
20. Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824.
21. Shimizu C, Kimura S, Yoshida Y et al. Acute leucoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome. Pediatr Nephrol 1994; 8: 483-485.
22. Koene HR, Kleijer M, Algra J et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
23. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011; 24: 203-216.
24. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008; 14: 1550-1560.
25. Terui Y, Mishima Y, Sugimura N et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009; 15: 2523-2530.
26. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
27. Perosa F, Favoino E, Vicenti C et al. Two structurally different rituximabspecific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol 2009; 182: 416-423.
28. Bezombes C, Grazide S, Garret C et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004; 104: 1166-1173.
29. Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta 2005; 1746: 284-294.
30. Binder M, Otto F, Mertelsmann R et al. The epitope recognized by rituximab. Blood 2006; 108: 1975-1978.
31. Perosa F, Favoino E, Caragnano MA et al. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinaselike phosphodiesterase 3b precursor. Blood 2006; 107: 1070-1077.